Evidence method
Level · gp.fundamentals.debt_to_revenue
112.50% · OPTIONAL · NOT_ENOUGH_HISTORY
RIGEL PHARMACEUTICALS INC. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.
Level · gp.fundamentals.debt_to_revenue
112.50% · OPTIONAL · NOT_ENOUGH_HISTORY
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
-1.67% · OPTIONAL · NOT_ENOUGH_HISTORY
Yoy · gp.fundamentals.revenue
80.58% · CORE · NOT_ENOUGH_HISTORY
Level · gp.fundamentals.inventory_revenue_ratio
8.74% · OPTIONAL · NOT_ENOUGH_HISTORY
Level · gp.fundamentals.operating_margin
23.95% · CORE · NOT_ENOUGH_HISTORY
Level · gp.fundamentals.sbc_revenue_ratio
6.23% · OPTIONAL · NOT_ENOUGH_HISTORY
Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.